Evidence map›Paper›PMID 28562331›Full record

ArticleOncotarget2017

Dual degradation signals destruct GLI1: AMPK inhibits GLI1 through β-TrCP-mediated proteasome degradation.

Rui Zhang, Sherri Y Huang, Kay Ka-Wai Li, Yen-Hsing Li, Wei-Hsuan Hsu, Guang Jun Zhang, Chun-Ju Chang, Jer-Yen Yang

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Sex-specific phenotypes in the aging mouse heart and consequences for chronic fibrosis.American journal of physiology. Heart and circulatory physiology · 2022
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Loss ofInternational journal of molecular sciences · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Rui ZhangDepartment of Basic Medical Sciences, West Lafayette, Indiana, USA.
Sherri Y HuangDepartment of Basic Medical Sciences, West Lafayette, Indiana, USA.
Kay Ka-Wai Li/F of Cancer Centre, Prince of Wales Hospital, Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong.
Yen-Hsing LiDepartment of Basic Medical Sciences, West Lafayette, Indiana, USA.
Wei-Hsuan HsuDepartment of Basic Medical Sciences, West Lafayette, Indiana, USA.
Guang Jun ZhangCenter for Cancer Research, Purdue University, West Lafayette, Indiana, USA.
Chun-Ju ChangDepartment of Basic Medical Sciences, West Lafayette, Indiana, USA.
Jer-Yen YangDepartment of Basic Medical Sciences, West Lafayette, Indiana, USA.
Center for Cancer Research · USPrince of Wales Hospital · CNPurdue University West Lafayette · US

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI John Tesmer · 1985 to 2026
$43.4M
NCI NIH HHS P30 CA023168
6 · The paper itself

Abstract

Overexpression of the GLI1 gene has frequently been found in various cancer types, particularly in brain tumors, in which aberrant GLI1 induction promotes cancer cell growth. Therefore, identifying the molecular players controlling GLI1 expression is of clinical importance. Previously, we reported that AMPK directly phosphorylated and destabilized GLI1, resulting in the suppression of the Hedgehog signaling pathway. The current study not only demonstrates that AMPK inhibits GLI1 nuclear localization, but further reveals that β-TrCP plays an essential role in AMPK-induced GLI1 degradation. We found that activation of AMPK promotes the interaction between β-TrCP and GLI1, and induces β-TrCP-mediated GLI1-ubiquitination and degradation. Inhibiting AMPK activity results in the dissociation of the β-TrCP and GLI1 interaction, and diminishes β-TrCP-mediated-GLI1 ubiquitination and degradation. On GLI1, substitution of AMPK phosphorylation sites to aspartic acid (GLI13E) results in stronger binding affinity of GLI1 with β-TrCP, accompanied by enhanced GLI1 ubiquitination and later degradation. In contrast, the GLI1 alanine mutant (GLI13A) shows weaker binding with β-TrCP, which is accompanied by reduced β-TrCP-mediated ubiquitination and degradation. Together, these results demonstrate that AMPK regulates GLI1 interaction with β-TrCP by phosphorylating GLI1 and thus both post-translational modifications by AMPK and β-TrCP ultimately impact GLI1 degradation.

Indexed as

Signal TransductionActive Transport, Cell NucleusAMP-Activated Protein KinasesAnimalsbeta-Transducin Repeat-Containing ProteinsCell Line, TumorCell ProliferationGene ExpressionHumansMiceNeoplasmsPhosphorylationProteasome Endopeptidase ComplexProtein TransportProteolysisUbiquitinationAMP-Activated Protein Kinasesbeta-Transducin Repeat-Containing ProteinsProteasome Endopeptidase ComplexZinc Finger Protein GLI1AMPKGLI1Hedgehogmedulloblastomaβ-transducin repeat containing protein (β-TrCP)

Identifiers

PMID28562331
PMCPMC5564814
OpenAlexW2613509795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.